SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Genaissance Pharmaceuticals (GNSC)
An SI Board Since September 2000
Posts SubjectMarks Bans Symbol
183 6 0 GNSC
Emcee:  Jim Oravetz Type:  Unmoderated
NEW HAVEN, CT,Aug 29,2000/PRNewswire/ - Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) today announced that the underwriters of its recent initial public offering of common stock have exercised in full their option to purchase from Genaissance an additional 900,000 shares at the initial public offering price of $13 per share. Net proceeds of the Company's initial public offering, including the exercise of the over-allotment, are $89.7 million.

After giving effect to the sale of the over-allotment shares, a total of 6,900,000 shares of common stock were offered and sold in the offering. Deutsche Banc Alex. Brown, Bear, Stearns & Co. Inc., Salomon Smith Barney and UBS Warburg LLC were the underwriters for the offering. Copies of the final prospectus may be obtained from Deutsche Banc Alex. Brown, Prospectus Department, One South Street, Baltimore, MD 21202.

Genaissance Pharmaceuticals is a leader in developing technology for applying population genomics and informatics to improve the development, marketing and prescribing of drugs. Genaissance discovers genomic markers that are predictive of which patients will respond effectively to a drug. The Company markets its technology to the pharmaceutical industry as a complete solution for developing "smarter" clinical trials and for improving the sales of existing drugs. The Genaissance solution combines informatics, proprietary genomic markers and an efficient procedure for analyzing clinical samples to correlate drug response with each patient's DNA. Genaissance is located in Science Park in New Haven, Connecticut. Additional information can be found at genaissance.com.

9/8/00 Briefing.com
10:16 ET Genaissance Pharma (GNSC) 23 13/16 +1 7/8 (+8.5%): Issue started with a BUY rating and $32 price target at Salomon Smith Barney. Firm served as a co-manager of GNSC's recent IPO.

Starting a new thread mostly because I'm interested in "local" biotechs in the New Haven area. This is another one along with VION, ALXN, CRGN, NRGN.

Jim
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
183Posted in CLDA thread: Message 22663025 "Going forward, a key objective isJim Oravetz-7/27/2006
182CLDA deserves a thread--I can't find one, anybody seen a Clinical Data threMike McFarland-2/5/2006
181Clinical Data Completes Acquisition of Genaissance Pharmaceuticals Clinical DatJim Oravetz-10/10/2005
180News On Genaissance (GNSC) Now Under (CLDA) DOW JONES NEWSWIRES October 7, 2005 Jim Oravetz-10/10/2005
179Genaissance Pharmaceuticals And Ipsogen Announce Cancer Biomarker Research AgreeJim Oravetz-9/12/2005
178Genaissance Pharma 2Q Loss 12c/Shr Vs 26c DOW JONES NEWSWIRES August 9, 2005 9:4Jim Oravetz-8/9/2005
177Genaissance Pharmaceuticals Enters into HAP(TM) Technology License Agreement witnigel bates-7/19/2005
176Genaissance to fetch $56 million in stock Damian J. Troise , Register Staff Jim Oravetz-6/22/2005
175Clinical Data To Buy Genaissance Pharmaceuticals; Combined Co To Deliver IndustrJim Oravetz-6/21/2005
174Genaissance test rules out disorder in Schiavo autopsy Abram Katz , Register SJim Oravetz-6/20/2005
173Genaissance Reports First Quarter 2005 Results NEW HAVEN, Conn., May 3 /PRNewswnigel bates-5/3/2005
172Genaissance and ParAllele BioScience Sign License and Co-Marketing Agreement Wednigel bates-4/6/2005
171Well maybe glgc will finally pull ahead; and for whatever reason, yahoo chart quMike McFarland-3/29/2005
170FOOTNOTES: Recent Going-Concern Statements DOW JONES NEWSWIRES March 28, 2005 5:Jim Oravetz-3/29/2005
169Eight weeks later, nothing has changed, same marketcaps, and neither seems to Mike McFarland-3/23/2005
168Genaissance Comments on FDA Guidance on Pharmacogenomics Tuesday March 22, 12:00nigel bates-3/22/2005
167It doesn’t sound like there’s much upside in this deal for GNSC other than the pDewDiligence_on_SI-3/10/2005
166Monsanto Teams With Biotech Co, USDA To Map Soybean's DNA DOW JONES NEWSWIREJim Oravetz-3/10/2005
165gnsc lists net assets of -5M and carries a MC of 51m. That seems exceedingly rMike McFarland-1/27/2005
164<i>interesting....</i> enough to knock 10% of the price. ;-) Tempnigel bates-1/26/2005
163<i>I don't follow gnsc, but this looks interesting.</i> Genaisskeokalani'nui-1/26/2005
162Genaissance Allowed Patent for Novel Methods to Correlate Genetics With Drug Safnigel bates-1/4/2005
161Genaissance Identifies Genetic Markers Implicated in Fatal Side Effects Of Schiznigel bates-12/20/2004
160Genaissance Pharmaceuticals Updates Guidance for 2004 Revenue Thursday October 2Jim Oravetz-10/21/2004
159SemiOT: Now on his own, Genaissance founder Ruano has big plans for thinking smaJim Oravetz-10/7/2004
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):